Author(s)

Bill Elliot Cham

Australasian Medical Research, Port Vila, Republic of Vanuatu.

Non-melanoma skin cancers or keratinocyte cancers such as basal cell carcinoma and squamous cell carcinoma make up approximately 80% and 20% respectively, of skin cancers with the 6 million people that are treated annually in the United States. 1 in 5 Americans and 2 in 3 Australians develop skin cancer by the age of 70 years and in Australia it is the most expensive, amassing $1.5 billion, to treat cancers. Non-melanoma skin cancers are often self-detected and are usually removed by various means in doctors’ surgeries. Mohs micrographic surgery is acclaimed to be the gold standard for the treatment of skin cancer. However, a novel microscopic molecular-cellular non-invasive topical therapy described in this article, challenges the status of Mohs procedure for being the acclaimed gold standard.

Skin Cancer, Basal Cell Carcinoma, Squamous Cell Carcinoma, Mohs Surgery, Microscopic Molecular-Cellular, Curaderm, Actinic Keratosis, Cosmesis

Cham, B. (2024) Gold Standard for Skin Cancer Treatment: Surgery (Mohs) or Microscopic Molecular-Cellular Therapy (Curaderm)?. Journal of Cancer Therapy, 15, 33-47. doi: 10.4236/jct.2024.152004.